Eureka Forbes Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: August 29, 2025, 1:24 pm

Quick Insight

Eureka Forbes Ltd, with a share price of 575 and a market capitalization of 11,122 Cr., is currently trading at a P/E ratio of 66.6, indicating a premium valuation in the domestic appliances industry. The company's ROE stands at 3.72%, while ROCE is at 5.07%, reflecting moderate returns on equity and capital employed. With an OPM of 10% and a net profit of 163 Cr., Eureka Forbes faces challenges in efficiency and profitability. The firm's healthy reserves of 4,191 Cr. provide stability, although the borrowing of ₹26 Cr. raises leverage concerns. Overall, investors should carefully monitor operational efficiency and profitability improvements to gauge the company's future performance.

Competitors of Eureka Forbes Ltd

All Competitor Stocks of Eureka Forbes Ltd

Quarterly Result

Last Updated: August 19, 2025, 3:46 pm

Below is a detailed analysis of the quarterly data for Eureka Forbes Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 608.00 Cr.. The value appears to be declining and may need further review. It has decreased from 613.00 Cr. (Mar 2025) to 608.00 Cr., marking a decrease of 5.00 Cr..
• For Expenses, as of Jun 2025, the value is 546.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 535.00 Cr. (Mar 2025) to 546.00 Cr., marking an increase of 11.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 61.00 Cr.. The value appears to be declining and may need further review. It has decreased from 78.00 Cr. (Mar 2025) to 61.00 Cr., marking a decrease of 17.00 Cr..
• For OPM %, as of Jun 2025, the value is 10.00%. The value appears to be declining and may need further review. It has decreased from 13.00% (Mar 2025) to 10.00%, marking a decrease of 3.00%.
• For Other Income, as of Jun 2025, the value is 7.00 Cr.. The value appears strong and on an upward trend. It has increased from 6.00 Cr. (Mar 2025) to 7.00 Cr., marking an increase of 1.00 Cr..
• For Interest, as of Jun 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.00 Cr..
• For Depreciation, as of Jun 2025, the value is 16.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 15.00 Cr. (Mar 2025) to 16.00 Cr., marking an increase of 1.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 52.00 Cr.. The value appears to be declining and may need further review. It has decreased from 68.00 Cr. (Mar 2025) to 52.00 Cr., marking a decrease of 16.00 Cr..
• For Tax %, as of Jun 2025, the value is 25.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 25.00%.
• For Net Profit, as of Jun 2025, the value is 39.00 Cr.. The value appears to be declining and may need further review. It has decreased from 51.00 Cr. (Mar 2025) to 39.00 Cr., marking a decrease of 12.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 1.99. The value appears to be declining and may need further review. It has decreased from 2.62 (Mar 2025) to 1.99, marking a decrease of 0.63.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 1:32 pm

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: August 11, 2025, 3:55 pm

Below is a detailed analysis of the balance sheet data for Eureka Forbes Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 193.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 193.00 Cr..
• For Reserves, as of Mar 2025, the value is 4,191.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,010.00 Cr. (Mar 2024) to 4,191.00 Cr., marking an increase of 181.00 Cr..
• For Borrowings, as of Mar 2025, the value is 26.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 39.00 Cr. (Mar 2024) to 26.00 Cr., marking a decrease of 13.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 1,899.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,878.00 Cr. (Mar 2024) to 1,899.00 Cr., marking an increase of 21.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 6,310.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 6,120.00 Cr. (Mar 2024) to 6,310.00 Cr., marking an increase of 190.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 5,468.00 Cr.. The value appears strong and on an upward trend. It has increased from 5,457.00 Cr. (Mar 2024) to 5,468.00 Cr., marking an increase of 11.00 Cr..
• For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1.00 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 1.00 Cr..
• For Investments, as of Mar 2025, the value is 84.00 Cr.. The value appears strong and on an upward trend. It has increased from 80.00 Cr. (Mar 2024) to 84.00 Cr., marking an increase of 4.00 Cr..
• For Other Assets, as of Mar 2025, the value is 758.00 Cr.. The value appears strong and on an upward trend. It has increased from 582.00 Cr. (Mar 2024) to 758.00 Cr., marking an increase of 176.00 Cr..
• For Total Assets, as of Mar 2025, the value is 6,310.00 Cr.. The value appears strong and on an upward trend. It has increased from 6,120.00 Cr. (Mar 2024) to 6,310.00 Cr., marking an increase of 190.00 Cr..

Notably, the Reserves (4,191.00 Cr.) exceed the Borrowings (26.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Eureka Forbes Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 8.46. This value is within the healthy range. It has increased from 4.94 (Mar 24) to 8.46, marking an increase of 3.52.
• For Diluted EPS (Rs.), as of Mar 25, the value is 8.46. This value is within the healthy range. It has increased from 4.93 (Mar 24) to 8.46, marking an increase of 3.53.
• For Cash EPS (Rs.), as of Mar 25, the value is 11.49. This value is within the healthy range. It has increased from 7.74 (Mar 24) to 11.49, marking an increase of 3.75.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 227.86. It has increased from 218.47 (Mar 24) to 227.86, marking an increase of 9.39.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 227.86. It has increased from 218.47 (Mar 24) to 227.86, marking an increase of 9.39.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 125.95. It has increased from 113.15 (Mar 24) to 125.95, marking an increase of 12.80.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 14.48. This value is within the healthy range. It has increased from 10.72 (Mar 24) to 14.48, marking an increase of 3.76.
• For PBIT / Share (Rs.), as of Mar 25, the value is 11.48. This value is within the healthy range. It has increased from 7.93 (Mar 24) to 11.48, marking an increase of 3.55.
• For PBT / Share (Rs.), as of Mar 25, the value is 11.41. This value is within the healthy range. It has increased from 6.64 (Mar 24) to 11.41, marking an increase of 4.77.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 8.50. This value is within the healthy range. It has increased from 4.94 (Mar 24) to 8.50, marking an increase of 3.56.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 8.50. This value is within the healthy range. It has increased from 4.94 (Mar 24) to 8.50, marking an increase of 3.56.
• For PBDIT Margin (%), as of Mar 25, the value is 11.49. This value is within the healthy range. It has increased from 9.47 (Mar 24) to 11.49, marking an increase of 2.02.
• For PBIT Margin (%), as of Mar 25, the value is 9.11. This value is below the healthy minimum of 10. It has increased from 7.00 (Mar 24) to 9.11, marking an increase of 2.11.
• For PBT Margin (%), as of Mar 25, the value is 9.05. This value is below the healthy minimum of 10. It has increased from 5.86 (Mar 24) to 9.05, marking an increase of 3.19.
• For Net Profit Margin (%), as of Mar 25, the value is 6.74. This value is within the healthy range. It has increased from 4.36 (Mar 24) to 6.74, marking an increase of 2.38.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 6.74. This value is below the healthy minimum of 8. It has increased from 4.36 (Mar 24) to 6.74, marking an increase of 2.38.
• For Return on Networth / Equity (%), as of Mar 25, the value is 3.72. This value is below the healthy minimum of 15. It has increased from 2.26 (Mar 24) to 3.72, marking an increase of 1.46.
• For Return on Capital Employeed (%), as of Mar 25, the value is 4.12. This value is below the healthy minimum of 10. It has increased from 2.96 (Mar 24) to 4.12, marking an increase of 1.16.
• For Return On Assets (%), as of Mar 25, the value is 2.59. This value is below the healthy minimum of 5. It has increased from 1.56 (Mar 24) to 2.59, marking an increase of 1.03.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.01. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.01.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.39. It has increased from 0.36 (Mar 24) to 0.39, marking an increase of 0.03.
• For Current Ratio (X), as of Mar 25, the value is 0.83. This value is below the healthy minimum of 1.5. It has increased from 0.63 (Mar 24) to 0.83, marking an increase of 0.20.
• For Quick Ratio (X), as of Mar 25, the value is 0.57. This value is below the healthy minimum of 1. It has increased from 0.37 (Mar 24) to 0.57, marking an increase of 0.20.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.62. This value is below the healthy minimum of 4. It has increased from 3.47 (Mar 24) to 3.62, marking an increase of 0.15.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 49.77. This value is within the healthy range. It has increased from 21.22 (Mar 24) to 49.77, marking an increase of 28.55.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 29.47. This value is within the healthy range. It has increased from 12.34 (Mar 24) to 29.47, marking an increase of 17.13.
• For Enterprise Value (Cr.), as of Mar 25, the value is 10,267.49. It has increased from 8,769.60 (Mar 24) to 10,267.49, marking an increase of 1,497.89.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.21. This value exceeds the healthy maximum of 3. It has increased from 4.01 (Mar 24) to 4.21, marking an increase of 0.20.
• For EV / EBITDA (X), as of Mar 25, the value is 36.65. This value exceeds the healthy maximum of 15. It has decreased from 42.28 (Mar 24) to 36.65, marking a decrease of 5.63.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.31. This value exceeds the healthy maximum of 3. It has increased from 4.04 (Mar 24) to 4.31, marking an increase of 0.27.
• For Price / BV (X), as of Mar 25, the value is 2.38. This value is within the healthy range. It has increased from 2.09 (Mar 24) to 2.38, marking an increase of 0.29.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.31. This value exceeds the healthy maximum of 3. It has increased from 4.04 (Mar 24) to 4.31, marking an increase of 0.27.
• For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness